Dr. Jiaxin (Jason) Niu earned his M.D. in China and Ph.D. in Molecular Pharmacology at the University of Illinois-Chicago. Dr. Niu completed his residency training in internal medicine at Cook County Hospital in Chicago and fellowship training in hematology/oncology at Baylor College of Medicine in Houston, Texas, USA.

Dr. Niu is a triple board-certified in internal medicine, hematology, and medical oncology. He currently works at Banner MD Anderson Cancer Center (BMDACC) as a thoracic/Head & Neck medical oncologist with clinical practice and research focus on lung, head & neck cancers. He serves as an Adjunct Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center and co-director of lung cancer program at BMDACC.

Dr. Niu has over 25 years of experience in both basic and clinical research. His research has been focusing on oncology drug development in the past 10 years. He is a prolific phase I trialist and has served as the Principal Investigator (PI) or Co-PI for over 40 oncology trials. He authored or co-authored more than 40 peer-reviewed publications in international journals from basic research to clinical studies. Of note, Dr. Niu was the site PI for Cemiplimab study, which led to FDA approval to treat advanced cutaneous squamous cell carcinoma, basal cell carcinoma and lung cancer. Dr. Niu also led an international phase I study on Vibostolimab, a TIGIT inhibitor, which is currently being studied in multiple phase II and phase III studies.

Dr Niu has also served as a consultant or an Advisory Board member for many biopharmaceutical companies including AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Takeda, etc.